- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02144155
Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia
3. december 2019 opdateret af: University of California, San Diego
Open-label Study of the Long-Term Efficacy of Intranasal Oxytocin in Patients With Schizophrenia
The Objective of this study is to investigate the long-term efficacy of intranasal oxytocin in improvement of symptoms in patients with schizophrenia who have residual symptoms dispute being on adequate treatment with antipsychotic medication.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Approximately 20 patients will be enrolled to participate in a 6 month flexible dose of oxytocin.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
14
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
California
-
San Diego, California, Forenede Stater, 92103
- UCSD Medical Center - Hillcrest
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Adult men or women, 18 years of age or older.
- Meet DSM-IV criteria for Schizophrenia
- Women of childbearing potential must test negative for pregnancy at the time of enrollment based on urine pregnancy test and agree to use a reliable method of birth control during the study.
- Must be on a therapeutic dose of 1 or 2 atypical antipsychotic medications (examples but not limited to Clozapine Olanzapine, Risperidone, Ziprasidone, Aripiprazole, Seroquel) with no major dose changes for at least 4 weeks.
- A minimum PANSS total score of 55 at baseline and a score of at least 4 (moderate) on the subscale of the PANSS (suspiciousness/persecution) at screening.
- Have a Clinical Global Impressions-Severity (CGI-S) scale score of at least 4 (moderately ill) at baseline;
- Must be able to communicate effectively with the investigator and study coordinator and have the ability to provide informed consent.
- Must be able to use nasal spray
- Must demonstrate an acceptable degree of compliance with medication and procedures in the opinion of the investigator.
Exclusion Criteria:
- Are pregnant or are breastfeeding (negative pregnancy test at screening)
- A urine drug screen performed at screening must not show evidence of recent use of drugs of abuse
- Any active medical condition that in the opinion of the investigator will interfere with the objectives of the study
- Are unsuitable in any way to participate in this study, in the opinion of the investigator.
- Another current, primary DSM-IV diagnosis other than Schizophrenia
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Oxytocin: 24 IU - 168 IU
Oxytocin twice daily for 3 weeks
|
Oxytocin: 24IU - 168 IU
|
Sham-komparator: Vehicle placebo
Placebo for 3 weeks
|
placebo lægemiddel
Oxytocin: 24IU - 168 IU
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Change in Total Score in the Positive and Negative Syndrome Scale (PANSS) From Baseline to 28 Weeks
Tidsramme: baseline and 28 weeks
|
The three subscales of the PANSS include the Positive scale (7 items), the Negative scale (7 items), and the General Psychopathology scale (16 items).
The total PANSS score is the sum of all 30 items of which each item is scored on a 1-7 rating system (7 indicating the worst symptoms).
The items on the PANSS focus on symptoms that are common in patients with psychotic disorders and include hallucinations, delusions and disorganization as well as mood disturbances.
|
baseline and 28 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Global Assessment of Functioning (GAF)
Tidsramme: 28 weeks
|
The GAF considers psychological, social, and occupational functioning on a hypothetical continuum of mental health illness.
Scores on the GAF range from 1 (extremely severe) to 100 (superior functioning).
|
28 weeks
|
Clinical Global Impression-Severity
Tidsramme: 28 Weeks
|
The CGI-S is used to evaluate changes in overall severity of illness.
Scores range from 1 (not at all) to 7 (among the most extremely ill).
|
28 Weeks
|
Clinical Global Impression-Global Improvement (CGI-I)
Tidsramme: 28 Weeks
|
The CGI-I is a global assessment to evaluate the subject's improvement or worsening from baseline.
Scores on the CGI-I scale range from 1 (very much improved) to 7 (very much worse).
|
28 Weeks
|
Computerized Multiphasic Interactive Neurocognitive DualDisplay TM System (CMINDS®)
Tidsramme: 28 weeks
|
28 weeks
|
|
Mayer-Salovey-Caruso Emotional Intelligence Test: Managing Emotions (MSCEIT™ ME)
Tidsramme: 28 Weeks
|
28 Weeks
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. marts 2012
Primær færdiggørelse (Faktiske)
1. december 2014
Studieafslutning (Faktiske)
1. december 2014
Datoer for studieregistrering
Først indsendt
19. maj 2014
Først indsendt, der opfyldte QC-kriterier
20. maj 2014
Først opslået (Skøn)
21. maj 2014
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
9. december 2019
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
3. december 2019
Sidst verificeret
1. december 2019
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 120005
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Placebo
-
SamA Pharmaceutical Co., LtdUkendtAkut bronkitis | Akut øvre luftvejsinfektionKorea, Republikken
-
National Institute on Drug Abuse (NIDA)AfsluttetBrug af cannabisForenede Stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAfsluttetMandlige forsøgspersoner med type II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAfsluttetFarmakokinetik | SikkerhedsproblemerDet Forenede Kongerige
-
Regado Biosciences, Inc.AfsluttetSund frivilligForenede Stater
-
Texas A&M UniversityNutraboltAfsluttetGlucose and Insulin Response
-
Longeveron Inc.AfsluttetHypoplastisk venstre hjerte syndromForenede Stater
-
ItalfarmacoAfsluttetBeckers muskeldystrofiHolland, Italien
-
West Penn Allegheny Health SystemAfsluttetAstma | Allergisk rhinitisForenede Stater